Mielóma multiplex: vizsgálatok itt: Spanyolország
80 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in SpanyolországElranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- Where
- Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pamplona, Salamanca, Santander, Valencia, Vitoria-Gasteiz
- Életkor
- 18 év and over
- People
- 60
- Run by
- PETHEMA Foundation
See details and how to joinNCT07901868 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Badalona, Barcelona, Cáceres, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela, Terrassa, Valencia
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peoplePhase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 387 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00 - 1/2. fázisTaking peopleA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Barcelona, Cáceres, Málaga, Sevilla
- Életkor
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00 - 1. fázisTaking peopleA Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00 - 3. fázisNot yet taking people in SpanyolországA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisFut, nem toborozA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 3. fázisTaking peopleA Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Badalona, Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00 - 2/3. fázisFut, nem toborozA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Where
- Badalona, Barcelona, Las Palmas De Gran Canaria, León, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Valencia
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00 - 2. fázisCsak meghívásosInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Badalona, Madrid, Pamplona, Salamanca, Santander, Seville
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989 - 3. fázisTaking peopleA Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- A Coruña, Badalona, Barcelona, Cáceres, Donostia, Granada, Jerez de la Frontera, León, Lugo, Madrid, Málaga, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01 - 3. fázisNot yet taking people in SpanyolországSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Badalona, Barcelona, Elche, Madrid, Santander
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 2. fázisNot yet taking people in SpanyolországMulticenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
- Where
- Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas De Gran Canaria, L'hospitalet De Llobregat, Lugo, Madrid, Marbella, Murcia, Oviedo, Palma, Pamplona, Salamanca, Santander, Valencia, Vitoria
- Életkor
- 18 év and over
- People
- 60
- Run by
- Fundacion PETHEMA
See details and how to join2026-526352-31-00 - 3. fázisNot yet taking people in SpanyolországA trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Badalona, Barcelona, Madrid, Murcia, Salamanca, Santander, Sevilla
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00 - No phaseTaking peopleEffects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 32
- Run by
- Universidad Complutense de Madrid
See details and how to joinNCT07312942 - No phaseTaking peopleEffects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 26
- Run by
- Universidad Complutense de Madrid
See details and how to joinNCT07376733 - 3. fázisTaking peopleA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid
- Életkor
- 18 év and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - 3. fázisTaking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - 2. fázisTaking peopleA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Where
- Badalona, Barcelona, Jerez de la Frontera, Madrid, Murcia, Pozuelo de Alarcón, Salamanca
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - 2. fázisCsak meghívásosLong-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
- Where
- Barcelona
- Életkor
- 1 év and over
- People
- 500 worldwide
- Run by
- Autolus Limited
See details and how to joinNCT03628612 - 1/2. fázisBefejeződöttStudy to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Murcia, Palma, Sevilla
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00 - 3. fázisTaking peopleA long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Barcelona
- Életkor
- 18 év and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 - 2. fázisTaking peoplePhase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Where
- Barcelona, León, Madrid, Málaga, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-524793-42-00 - 3. fázisNot yet taking people in SpanyolországA trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 234 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524014-29-00